
|Articles|May 15, 2005
Genetic, molecular anomalies determine RCC therapy
Management of kidney cancer is advancing on several fronts, and this theme of continued progress is well illustrated by research being presented at the AUA annual meeting, said Robert C. Flanigan, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
3
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











